IBD 50 Stock Natera Zips Into Profit-Taking Zone On Its Blowout Quarter

Natera (NTRA) stock surged Friday after the company reported what an analyst called "blowout volume" for its cancer-detecting blood test, Signatera, in the second quarter. Signatera is a personalized blood test that looks for microscopic pieces of tumor DNA in the blood. Doctors can use it to screen for whether cancer has returned following treatment. During the second quarter, 34,000…